The indications for allogeneic stem cell transplantation in myeloid malignancies.
BACKGROUND
The overall incidence of myeloid malignancies is 8.6 per 100 000 persons. Allogeneic stem-cell transplantation (SCT) is a major therapeutic option despite its risks, which include graft-versus-host disease (GvHD) and infection. In Germany, about 1600 patients with myeloid malignancies undergo SCT each year. The indications for SCT have changed since the introduction of tyrosine kinase inhibitors (TKI) and improved methods of SCT.


METHODS
This article is based on relevant guidelines from Germany and abroad and on a selective review of the literature from 2010 onward.


RESULTS
The individual indication for SCT is based on the risk of disease progression, accompanying illnesses, the probability that SCT will result in cure, and the risk of complications. There is good evidence favoring allogeneic SCT in the following situations affecting 20% to 50% of patients with the respective disease: advanced chronic myeloid leukemia (CML) or CML that does not respond to TKI, Philadelphia chromosome-negative myeloproliferative neoplasm (Ph- MPN) or myelodysplastic syndrome (MDS) with a high risk of progression, and acute myeloid leukemia (AML) that has high-risk cytogenetic features or is recurrent. Good evidence is accumulating in favor of allogeneic SCT in older patients as well.


CONCLUSIONS
The prognosis of patients with myeloid neoplasm can now be assessed more accurately than before. This facilitates well-founded clinical decision-making about SCT, which is the only potentially curative treatment for most patients with myeloid neoplasm. Patients up to about age 75 should be referred to a transplantation center for consultation at an early stage of their disease so that the treatment options can be evaluated. A major goal of current research is to reduce toxicity with innovative forms of treatment.
Department of Internal Medicine IV, University Hospital of Halle (Saale).
Lutz P
LP
Müller
Carsten
C
Müller-Tidow
D064591:Allografts; D000066491:Clinical Decision-Making / Q000379:methods*; D006084:Graft Rejection / Q000209:etiology / Q000517:prevention & control*; D006801:Humans; D007951:Leukemia, Myeloid / Q000473:pathology / Q000628:therapy*; D009190:Myelodysplastic Syndromes / Q000473:pathology / Q000628:therapy*; D018570:Risk Assessment; D033581:Stem Cell Transplantation / Q000009:adverse effects / Q000379:methods*; D016896:Treatment Outcome